Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Ian Pavord, Roland Buhl, Monica Kraft, Charlene M. Prazma, Robert G. Price, Peter Howarth, Steven W. Yancey
Abstract
<b>In patients with severe eosinophilic asthma and sputum eosinophil counts of ≥3–<30%, sputum eosinophils may not represent a more useful biomarker than blood eosinophils for predicting clinical treatment response to mepolizumab</b>https://bit.ly/3pOTw93
Topics & Concepts
MepolizumabMedicineSputumEosinophilBiomarkerAsthmaImmunologyEosinophiliaInternal medicinePathologyTuberculosisBiochemistryChemistryAsthma and respiratory diseasesEosinophilic EsophagitisRespiratory and Cough-Related Research